# MOTS-c

Type: Product

Source: Legal & RegTech Intelligence Brief — https://getlegalbrief.com/entity/mots-c
Canonical HTML page: https://getlegalbrief.com/entity/mots-c

## Timeline

- **2026-07-24**: PCAC Votes to Recommend Six Peptides — The committee votes to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for inclusion on the 503A Bulks List, culminating the multi-day review.
- **2026-07-23**: FDA PCAC Public Meeting Begins — The Pharmacy Compounding Advisory Committee commences a two-day meeting to review nominations of bulk drug substances, including six peptide candidates, for the 503A Bulks List.

## Recent coverage (1 stories)

### FDA Panel Backs 6 Peptides for 503A List, Legal Framework Looms
2026-08-01 14:26:07 · Sentiment: Very Bullish · Impact: 6/10 · Sources: 2

The FDA advisory committee recommended six peptide substances for the 503A Bulks List, a critical regulatory step that could reshape compounding pharmacy law. Vanta is proactively building a compliant telehealth and manufacturing infrastructure, anticipating the rule change.
Full story: https://getlegalbrief.com/story/fda-advisory-vote-six-peptides-503a-legal

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getlegalbrief.com/guides/methodology for the full editorial methodology.